表紙:レストレスレッグス症候群(中枢神経系):開発中の薬剤(2021年)
市場調査レポート
商品コード
1000814

レストレスレッグス症候群(中枢神経系):開発中の薬剤(2021年)

Restless Legs Syndrome (Central Nervous System) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 57 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
レストレスレッグス症候群(中枢神経系):開発中の薬剤(2021年)
出版日: 2021年03月31日
発行: Global Markets Direct
ページ情報: 英文 57 Pages
納期: 即納可能 即納可能とは
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レストレスレッグス症候群(RLS)は、ウィリスエクボム病(WED)とも呼ばれ、神経系の一部の障害で、脚に影響を及ぼし、脚を動かしたいという衝動を引き起こします症状としては、ふくらはぎや脚のかゆみ、痛み、ゾクゾクするような感覚、けいれんなどがあり、病因には年齢が挙げられます。治療法としては、筋弛緩剤、睡眠薬、麻酔薬の投与などがあります。

当レポートは、レストレスレッグス症候群(中枢神経系)の開発中の薬剤について調査しており、世界の治療情勢、パイプライン治療法のレビュー、開発、パイプライン製品の薬剤プロファイル、主要企業のレビュー、レストレスレッグス症候群のパイプライン治療に関する最新ニュースなどの情報を提供しています。

目次

  • イントロダクション
  • 世界の市場直属の部下の報道
  • レストレスレッグス症候群-概要
  • レストレスレッグス症候群-治療法の開発
  • パイプラインの概要
  • 企業別パイプライン
  • 企業が開発中の製品
  • レストレスレッグス症候群-治療評価
  • ターゲット別評価
  • 作用機序別評価
  • 投与経路別評価
  • 分子タイプ別評価
  • レストレスレッグス症候群-治療法開発に関与する企業
  • Axim Biotechnologies Inc
  • Bioprojet SCR
  • Hisamitsu Pharmaceutical Co Inc
  • Luye Pharma Group Ltd
  • NLS Pharma Group
  • Omeros Corp
  • Relmada Therapeutics Inc
  • Seelos Therapeutics, Inc.
  • Serina Therapeutics Inc
  • Vifor Pharma Ltd
  • レストレスレッグス症候群-薬剤プロファイル
  • (カンナビジオール+ドロナビノール)-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • aplindorefumarate-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • BP-1.4979-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • カルボキシマルトース第二鉄-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • LY-03009-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • NLS-2-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • OMS-527-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • REL-1017-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • ロピニロール塩酸塩CR-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • SER-214-薬剤プロファイル
  • 製品概要
  • 作用機序
  • 研究開発の進捗状況
  • レストレスレッグス症候群-休眠プロジェクト
  • レストレスレッグス症候群-製造中止製品
  • レストレスレッグス症候群-製品開発のマイルストーン
  • 注目のニュースとプレスリリース
  • 2021年1月4日:Luye Pharma Group:LY03009がオーストラリアで第I相臨床試験を開始
  • 2014年10月23日:Hisamitsuが日本におけるHP-3000の第II相臨床試験の結果を発表(特発性レストレスレッグス症候群の治療のための経皮システム)
  • 2013年3月25日:米国特許商標庁によるパーキンソン病とレストレスレッグス症候群の主な臨床候補をカバーするSerinaTherapeuticsの主要特許授与
  • 2008年10月16日:Neurogenによるレストレスレッグス症候群とパーキンソン病におけるアプリンドレの2つの第II相試験からの肯定的なトップラインの結果の発表
  • 付録
  • 調査手法
  • 調査範囲
  • 2次調査
  • 1次調査
  • エキスパートパネルの検証
  • お問い合わせ
  • 免責事項
図表

List of Tables

  • Number of Products under Development for Restless Legs Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Restless Legs Syndrome - Pipeline by Axim Biotechnologies Inc, 2021
  • Restless Legs Syndrome - Pipeline by Bioprojet SCR, 2021
  • Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co Inc, 2021
  • Restless Legs Syndrome - Pipeline by Luye Pharma Group Ltd, 2021
  • Restless Legs Syndrome - Pipeline by NLS Pharma Group, 2021
  • Restless Legs Syndrome - Pipeline by Omeros Corp, 2021
  • Restless Legs Syndrome - Pipeline by Relmada Therapeutics Inc, 2021
  • Restless Legs Syndrome - Pipeline by Seelos Therapeutics, Inc., 2021
  • Restless Legs Syndrome - Pipeline by Serina Therapeutics Inc, 2021
  • Restless Legs Syndrome - Pipeline by Vifor Pharma Ltd, 2021
  • Restless Legs Syndrome - Dormant Projects, 2021
  • Restless Legs Syndrome - Discontinued Products, 2021

List of Figures

  • Number of Products under Development for Restless Legs Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC12761IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Drugs in Development, 2021, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape.

Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling and cramping in the calf's or legs. Predisposing factor includes age. Treatment includes muscle relaxants, sleep medications and narcotic medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Restless Legs Syndrome - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 3 and 2 respectively.

Restless Legs Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Restless Legs Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Restless Legs Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Restless Legs Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Restless Legs Syndrome (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Restless Legs Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Restless Legs Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Restless Legs Syndrome - Overview
  • Restless Legs Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Restless Legs Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Restless Legs Syndrome - Companies Involved in Therapeutics Development
  • Axim Biotechnologies Inc
  • Bioprojet SCR
  • Hisamitsu Pharmaceutical Co Inc
  • Luye Pharma Group Ltd
  • NLS Pharma Group
  • Omeros Corp
  • Relmada Therapeutics Inc
  • Seelos Therapeutics, Inc.
  • Serina Therapeutics Inc
  • Vifor Pharma Ltd
  • Restless Legs Syndrome - Drug Profiles
  • (cannabidiol + dronabinol) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aplindore fumarate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BP-1.4979 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ferric carboxymaltose - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-03009 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NLS-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OMS-527 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • REL-1017 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ropinirole hydrochloride CR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SER-214 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Restless Legs Syndrome - Dormant Projects
  • Restless Legs Syndrome - Discontinued Products
  • Restless Legs Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Jan 04, 2021: Luye Pharma Group: LY03009 commenced phase I clinical trial in Australia
  • Oct 23, 2014: Hisamitsu Announces the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)
  • Mar 25, 2013: US Patent and Trademark Office awards Serina Therapeutics key patent covering its lead clinical candidate for Parkinson's disease and restless leg syndrome
  • Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer